ZA96576B - Extended-release solid oral dosage forms of drugs having low solubility in water - Google Patents

Extended-release solid oral dosage forms of drugs having low solubility in water

Info

Publication number
ZA96576B
ZA96576B ZA96576A ZA96576A ZA96576B ZA 96576 B ZA96576 B ZA 96576B ZA 96576 A ZA96576 A ZA 96576A ZA 96576 A ZA96576 A ZA 96576A ZA 96576 B ZA96576 B ZA 96576B
Authority
ZA
South Africa
Prior art keywords
drugs
extended
water
dosage forms
oral dosage
Prior art date
Application number
ZA96576A
Other languages
English (en)
Inventor
Bernard Charles Sherman
Original Assignee
Bernard Charles Sherman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bernard Charles Sherman filed Critical Bernard Charles Sherman
Publication of ZA96576B publication Critical patent/ZA96576B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA96576A 1995-02-02 1996-01-25 Extended-release solid oral dosage forms of drugs having low solubility in water ZA96576B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NZ270439A NZ270439A (en) 1995-02-02 1995-02-02 Solid slow release pharmaceutical composition: carrier is polyethylene glycol and hydrophilic gel-forming polymer

Publications (1)

Publication Number Publication Date
ZA96576B true ZA96576B (en) 1996-08-14

Family

ID=19925135

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA96576A ZA96576B (en) 1995-02-02 1996-01-25 Extended-release solid oral dosage forms of drugs having low solubility in water

Country Status (8)

Country Link
US (1) US6132772A (fr)
EP (1) EP0809497A1 (fr)
AU (1) AU706699B2 (fr)
CA (1) CA2212309C (fr)
IL (1) IL116993A0 (fr)
NZ (1) NZ270439A (fr)
WO (1) WO1996023499A1 (fr)
ZA (1) ZA96576B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ286451A (en) * 1996-04-24 1998-04-27 Bernard Charles Sherman Controlled release pharmaceutical composition containing granules comprising drug, water-insoluble polymer and meltable carrier
EP1175205B1 (fr) * 1999-11-12 2006-06-14 Abbott Laboratories Dispersion solide comrpenant ritonavir, fenofibrate ou griseofulvin
US7364752B1 (en) * 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
SE0004671D0 (sv) * 2000-12-15 2000-12-15 Amarin Dev Ab Pharmaceutical formulation
BE1014450A6 (nl) * 2000-12-29 2003-10-07 Bioorg Bv Werkwijze voor het maken van amlodipine, derivaten daarvan en voorlopers daarvoor.
ES2261643T3 (es) * 2001-02-13 2006-11-16 Astrazeneca Ab Nueva formulacion de liberacion modificada.
JP4644397B2 (ja) * 2001-09-05 2011-03-02 信越化学工業株式会社 難溶性薬物を含む医薬用固形製剤の製造方法
US20040001886A1 (en) * 2001-10-17 2004-01-01 Dr. Reddy's Laboratories Limited Stabilized pharmaceutical formulations containing amlodipine maleate
BE1014922A3 (nl) * 2002-03-01 2004-06-01 Pfizer Ltd Amlodipine als vrije base.
US20030211149A1 (en) * 2002-05-07 2003-11-13 Sherman Bernard Charles Extended release tablets comprising felodipine
JP4563642B2 (ja) * 2002-05-31 2010-10-13 ワトソン ラボラトリーズ、インコーポレイテッド 医薬製剤
KR20040011248A (ko) * 2002-07-30 2004-02-05 환인제약 주식회사 암로디핀의 고체분산체와 그 제조방법 및 그를 포함하는약학적 조성물
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US7413690B1 (en) 2003-10-29 2008-08-19 The University Of Mississippi Process and apparatus for producing spherical pellets using molten solid matrices
EP1690528A1 (fr) * 2005-02-11 2006-08-16 Abbott GmbH & Co. KG Procedé pour la préparation des formes de dosage comprenant une dispersion solide d'un agent active microcristalline
CN100382800C (zh) * 2006-03-07 2008-04-23 中国药科大学 联苯双酯固体分散体、其制备方法及含其的缓释制剂
WO2010099508A1 (fr) 2009-02-26 2010-09-02 Theraquest Biosciences, Inc. Compositions pharmaceutiques orales à libération prolongée de 3-hydroxy-n-méthylmorphinane et procédé d'utilisation
WO2014051443A1 (fr) * 2012-09-27 2014-04-03 Mendoza Wendell G Procédé de fabrication de comprimés à matrice de cire-citrate de potassium à libération prolongée

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1579818A (en) * 1977-06-07 1980-11-26 Yamanouchi Pharma Co Ltd Nifedipine-containing solid preparation composition
CA1146866A (fr) * 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Procede de production d'un compose pharmaceutique a liberation continue sous forme solide
JPS56115726A (en) * 1980-02-20 1981-09-11 Kaken Pharmaceut Co Ltd Pharmaceutical containing nifedipine
US4765989A (en) * 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
ATE135214T1 (de) * 1992-02-17 1996-03-15 Siegfried Ag Pharma Darreichungsformen mit verlaengerter wirkstoffreigabe
BE1006990A5 (nl) * 1993-04-22 1995-02-07 Univ Gent Werkwijze en samenstelling om een aktief bestanddeel in een vaste toedieningsvorm te brengen.
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
JPH07291854A (ja) * 1994-04-26 1995-11-07 Tanabe Seiyaku Co Ltd 溶解性の改善された医薬品製剤

Also Published As

Publication number Publication date
AU706699B2 (en) 1999-06-24
IL116993A0 (en) 1996-05-14
US6132772A (en) 2000-10-17
AU4478496A (en) 1996-08-21
CA2212309A1 (fr) 1996-08-08
CA2212309C (fr) 2000-08-08
NZ270439A (en) 1996-04-26
EP0809497A1 (fr) 1997-12-03
WO1996023499A1 (fr) 1996-08-08

Similar Documents

Publication Publication Date Title
ZA96576B (en) Extended-release solid oral dosage forms of drugs having low solubility in water
IL117041A0 (en) Oral pharmaceutical dosage form
IL195339A0 (en) Solid oral dosage forms of valsartan
IL118637A (en) Oral pharmaceutical compositions of s(+)-ibuprofen
IL117237A (en) Pharmaceutical compositions of piperidinoalkanol compounds in solid unit dosage form
PL322579A1 (en) 2-methyl-thiene-benzodiazeoin prparation for oral administration
PL312064A1 (en) Soft gelatinous form of pharmaceutical dose
AU7375598A (en) Stable oral pharmaceutical dosage forms
HUP9903407A3 (en) Oral pharmaceutical preparation containing ibandronat
HUP9900751A3 (en) Stable pharmaceutical forms of administration containing parathormone
IL118636A (en) Oral pharmaceutical compositions of S(+)-etodolac
PL341230A1 (en) Solid dosage forms of ribavirin for oral administration and method of obtaining them
IL118162A0 (en) Nanoparticles for oral administration of pharmaceutical agents of low solubility
ZA964517B (en) Oral pharmaceutical composition of piperidinoalkanol compounds in solution form
ZA961081B (en) Pharmaceutical preparations for tnf inhibition
IL137496A0 (en) Dosage form and pharmaceutical kit for increasing the oral availablity of pharmaceutical agents
ZA967542B (en) Pharmaceutical combination preparation comprising keto-profen
ZA97210B (en) Oral administration of effective amunts of forms of hyaluronic acid
GB9504969D0 (en) Oral administration of proteinaceous drugs
AUPM590295A0 (en) Manufacture of pharmaceutical dosage forms
IL112923A0 (en) Pharmaceutical dosage form
ZA965472B (en) Dipeptide compound or pharmaceutically acceptable salt thereof and medical use thereof
GB9930266D0 (en) Oral administration of beneficial substances
IL105714A0 (en) Oral dosage forms of risedronate
IL105393A0 (en) Buoyant solid pharmaceutical dosage forms